Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery

• Status: Completed
• Trial end date: 2003-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Analgesics; Celecoxib

Criteria

Inclusion criteria:

• Diagnosed knee meniscus pathology requiring ambulatory arthroscopic meniscectomy or partial meniscectomy

• Willing to participate in study for 36 hours and come to follow-up visit 7 days post-surgery

Exclusion criteria:

• Osteoarthritis, inflammatory arthritis, or previous fracture of index joint

• Received acetaminophen or low-dose narcotic within 8 hours of surgery

• Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of corticosteroids of the first dose of study medication or received intra-articular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication